Online citations, reference lists, and bibliographies.
← Back to Search

Treatment Of Mesothelioma With Radiotherapy

R. P. Smith, S. Hahn
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Radiation therapy is a therapeutic modality that uses ionizing radiation to treat cancers and some nonmalignant conditions. Ionizing radiation kills cells by damaging DNA (1). Approximately two thirds of the DNA damage caused by ionizing radiation is from indirect action, that is, damage caused by free radicals generated mostly from the ionization of water (1). The remainder of the damage caused by radiation is through direct ionization of DNA. Radiation damage is also highly dependent on the presence of oxygen. The cytotoxicity of radiation is approximately three times greater in the presence of oxygen than that which occurs in an anoxic environment (1). Hypoxia in human tumors has been extensively investigated and may be a physiologic cause for radiation resistance (2–4). The absorbed dose of radiation therapy is prescribed in units called gray (Gy). The clinical use of radiation therapy in the United States is usually fractionated, that is, delivered in small doses daily. In general, for definitive or curative radiation therapy courses, a daily dose of 180 or 200cGy per day is used. A total dose of radiation therapy for a curative course is usually between 5000 and 7000cGy. For palliative courses of radiation therapy, daily doses between 250 and 400cGy are used for a total dose of between 2000 to 3500cGy. The biologic basis for fractionation is that greater tumor cell kill can be achieved with fractionation relative to normal tissue effects by exploiting the 4 Rs: cellular repair, reassortment of tumor cells into sensitive phases of the cell cycle, reoxygenation of tumor cells, and repopulation of normal tissues. The total dose of radiation therapy used clinically is, in general, dependent on the radiation doses that the normal tissues within the radiation field can tolerate (so-called tolerance doses). There are some tumors that are quite radioresponsive, and for these tumors, doses below normal tissue tolerances can be used. However, for most solid tumors, including mesothelioma, the dose of radiation therapy that is prescribed is based on the tolerance of the normal tissues. In the case of mesothelioma, normal tissues that are sensitive to the effects of radiotherapy are
This paper references
10.1097/00000421-199002000-00002
The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy
D. Ball (1990)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1982)
10.1016/S0167-8140(99)00102-4
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome.
D. Brizel (1999)
10.3109/02841869709001287
Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.
L. R. Holsti (1997)
10.1002/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W
Malignant mesothelioma of the pleura: Review of 123 patients
J. Brenner (1982)
10.5555/URI:PII:0093775481900427
Mesothelioma--the role for radiation therapy.
L. Brady (1981)
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
M. Law (1984)
Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
S. Evans (2000)
10.1016/S0360-3016(98)00409-X
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
10.1097/00000421-200110000-00004
Schedule-Dependent Pulsed Paclitaxel Radiosensitization for Thoracic Malignancy
Y. Chen (2001)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
Malignant peritoneal mesothelioma: review of 25 patients.
J. Brenner (1981)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1053/SRAO.2002.32433
Intensity-modulated radiation therapy: the inverse, the converse, and the perverse.
E. Glatstein (2002)
10.1093/AJCP/82.1.15
Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study.
V. Adams (1984)
Oncologic Therapies, Vokes EE & Golomb HM (eds), Springer-Verlag, Berlin Heidelberg, 1999
伊東 久夫 (1999)
10.1053/SRAO.2002.32435
Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets.
A. Eisbruch (2002)
10.1200/JCO.1998.16.2.635
Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.
L. Herscher (1998)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1002/1097-0142(195907/08)12:4<799::AID-CNCR2820120425>3.0.CO;2-L
Prolonged survival in diffuse pleural mesothelioma treated with AU198
R. Richart (1959)
10.1016/S0022-5347(05)65855-7
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
M. Zelefsky (2001)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/0360-3016(92)90709-Q
Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
K. Mattson (1992)
10.1111/J.1440-1673.1994.TB00177.X
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
S. Davis (1994)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1136/thx.39.4.255
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
M. Law (1984)
10.1097/00000421-200110000-00011
Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation
S. Evans (2001)
10.1183/09031936.96.09122565
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
10.7326/0003-4819-80-3-438_1
Radiobiology for the radiologist
E. J. Hall (1973)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar